Evidence map›Paper›PMID 29138921›Full record

ReviewJournal of gastroenterology2018

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.

Hidekazu Suzuki, Hideki Mori

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04901663 (Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial), which is not on this map. Cited by 77 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04901663 phase4completednot on this mapstarted 2021, after this paper: background citation

Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial

TypeinterventionalSponsorDow University of Health SciencesRan2021 to 2021Enrolled179ConditionsHelicobacter Pylori InfectionArmsOmeprazole 20 MG Capsule, Amoxicillin 1000 MG, Clarithromycin 500 MG, Vonoprazan 20 MG, Amoxicillin 1000 MG
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Helicobacter pylori Management in Older Adults: Current Perspectives From Japan.The Korean journal of helicobacter and upper gastrointestinal research · 2026
    Review
  7. Article
  8. Update on the pathogenesis and clinical management ofWorld journal of gastrointestinal pathophysiology · 2025
    Review
  9. The Prevalence ofEpidemiologia (Basel, Switzerland) · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Birth cohort and age-specific trends in globalLancet regional health. Americas · 2025
    Review
  14. Article
  15. Immune cell changes inAnnals of medicine · 2024
    Article
  16. Endoscopic Diagnosis of Early Gastric Cancer and High-Risk Gastritis.The Korean journal of helicobacter and upper gastrointestinal research · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Initiation of aJuntendo Iji zasshi = Juntendo medical journal · 2024
    Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Hidekazu SuzukiFellowship Training Center, Medical Education Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. hsuzuki.a6@keio.jp.
Hideki MoriDepartment of Gastroenterology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Keio University · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

Indexed as

Helicobacter pyloriAnti-Bacterial AgentsClarithromycinConsensusDisease EradicationDrug Resistance, BacterialGastritisHealth Planning GuidelinesHelicobacter InfectionsHumansIncidenceJapanMetronidazoleNational Health ProgramsQuinolonesRifabutinAnti-Bacterial AgentsClarithromycinMetronidazoleQuinolonesRifabutinClarithromycinFluoroquinoloneGastric cancerH. pyloriMetronidazole

Identifiers

PMID29138921
PMCPMC5847180
OpenAlexW2770464558

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.